AERIのチャート
AERIの企業情報
| symbol | AERI |
|---|---|
| 会社名 | Aerie Pharmaceuticals Inc （アエリ―・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アエリー･ファーマシューティカル(Aerie Pharmaceuticals Inc.)は臨床病期の製薬会社である。同社は緑内障及び眼の他の疾患の患者のための治療法の発見・開発・商業化に従事する。同社の製品候補には、Rhopressa（netarsudil点眼液）0.02％（Rhopressa）、Roclatan（netarsudil /ラタノプロスト点眼液）0.02％/ 0.005％（Roclatan）が含まれる。同社の製品候補は、開放隅角緑内障および高眼圧症患者の眼内圧（IOP）を下げるように設計される。そのRhopressaは1日1回の点眼薬である。Rhopressaは、IOPを低下させる生化学的標的であるRhoキナーゼ（ROCK）およびノルエピネフリントランスポーター（NET）を阻害する。そのRoclatanは、オープンアングルの緑内障患者の治療薬として処方されているRhopressaとlatanoprostの1日1回、固定用量の組み合わせである。同社はRoclatanの第III相臨床試験を実施している。 アエリ―・ファ―マシュ―ティカルズは米国の製薬会社。緑内障とその他目の疾患治療薬の発見、開発、商業化を行う。緑内障と高眼圧症向けに一日一回投薬で眼圧を下げるRhoキナ―ゼ阻害剤「ロ―プレッサ」と「ロクラタン」の第3相治験を行う。また、第2世代のRhoキナ―ゼ阻害剤が臨床前段階。本社はカリフォルニア州。 Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. |
| 本社所在地 | 4301 Emperor Boulevard Suite 400 Durham CA 27703 USA |
| 代表者氏名 | Vicente Anido ヴィセンテ・アニード |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 919-313-9650 |
| 設立年月日 | 38504 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 160人 |
| url | www.aeriepharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/aeri |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -187.08400 |
| 終値（lastsale） | 54.17 |
| 時価総額（marketcap） | 2449689445.01 |
| 時価総額 | 時価総額（百万ドル） 2406.276 |
| 売上高 | 売上高（百万ドル） 2.42300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 2244.172 |
| 当期純利益 | 当期純利益（百万ドル） -186.60800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Aerie Pharmaceuticals Inc revenues increased from $0K to $2.4M. Net loss increased 77% to $95.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative -Other increase from $22.6M to $53.3M (expense) Research and development - Other increase of 39% to $26.5M (expense). |
AERIのテクニカル分析
AERIのニュース
Aerie Pharma completes enrollment in first Phase 3 trial of netarsudil in Japan 2021/06/17 11:05:17 Seeking Alpha
Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan 2021/06/17 10:30:00 Wallstreet:Online
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the completion of patient enrollment for its first Phase 3 clinical trial of netarsudil ophthalmic solution in
Needham Issues a Buy Rating on Aerie Pharma (AERI) 2021/06/11 14:05:06 Smarter Analyst
In a report released today, Serge Belanger from Needham assigned a Buy rating to Aerie Pharma (AERI), with a price target of $26.00. The post Needham Issues a Buy Rating on Aerie Pharma (AERI) appeared first on Smarter Analyst .
Analysts Offer Insights on Healthcare Companies: Aerie Pharma (AERI) and AngioDynamics (ANGO) 2021/06/08 11:25:39 Smarter Analyst
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aerie Pharma (AERI) and AngioDynamics (ANGO). Aerie Pharma The post Analysts Offer Insights on Healthcare Companies: Aerie Pharma (AERI) and AngioDynamics (ANGO) appeared first on Smarter Analyst .
Aerie Pharma completes enrollment in first Phase 3 trial of netarsudil in Japan 2021/06/17 11:05:17 Seeking Alpha
Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan 2021/06/17 10:30:00 Wallstreet:Online
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the completion of patient enrollment for its first Phase 3 clinical trial of netarsudil ophthalmic solution in
Needham Issues a Buy Rating on Aerie Pharma (AERI) 2021/06/11 14:05:06 Smarter Analyst
In a report released today, Serge Belanger from Needham assigned a Buy rating to Aerie Pharma (AERI), with a price target of $26.00. The post Needham Issues a Buy Rating on Aerie Pharma (AERI) appeared first on Smarter Analyst .
Analysts Offer Insights on Healthcare Companies: Aerie Pharma (AERI) and AngioDynamics (ANGO) 2021/06/08 11:25:39 Smarter Analyst
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aerie Pharma (AERI) and AngioDynamics (ANGO). Aerie Pharma The post Analysts Offer Insights on Healthcare Companies: Aerie Pharma (AERI) and AngioDynamics (ANGO) appeared first on Smarter Analyst .
Analysts Offer Insights on Healthcare Companies: Cooper Co (COO) and Aerie Pharma (AERI) 2021/06/04 13:25:09 Smarter Analyst
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cooper Co (COO) and Aerie Pharma (AERI). Cooper The post Analysts Offer Insights on Healthcare Companies: Cooper Co (COO) and Aerie Pharma (AERI) appeared first on Smarter Analyst .
Aerie Pharma completes enrollment in first Phase 3 trial of netarsudil in Japan 2021/06/17 11:05:17 Seeking Alpha
Aerie Pharmaceuticals Completes Enrollment of its first Phase 3 Clinical Trial of Netarsudil Ophthalmic Solution in Japan 2021/06/17 10:30:00 Wallstreet:Online
Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the completion of patient enrollment for its first Phase 3 clinical trial of netarsudil ophthalmic solution in
Needham Issues a Buy Rating on Aerie Pharma (AERI) 2021/06/11 14:05:06 Smarter Analyst
In a report released today, Serge Belanger from Needham assigned a Buy rating to Aerie Pharma (AERI), with a price target of $26.00. The post Needham Issues a Buy Rating on Aerie Pharma (AERI) appeared first on Smarter Analyst .
Analysts Offer Insights on Healthcare Companies: Aerie Pharma (AERI) and AngioDynamics (ANGO) 2021/06/08 11:25:39 Smarter Analyst
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Aerie Pharma (AERI) and AngioDynamics (ANGO). Aerie Pharma The post Analysts Offer Insights on Healthcare Companies: Aerie Pharma (AERI) and AngioDynamics (ANGO) appeared first on Smarter Analyst .
Analysts Offer Insights on Healthcare Companies: Cooper Co (COO) and Aerie Pharma (AERI) 2021/06/04 13:25:09 Smarter Analyst
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cooper Co (COO) and Aerie Pharma (AERI). Cooper The post Analysts Offer Insights on Healthcare Companies: Cooper Co (COO) and Aerie Pharma (AERI) appeared first on Smarter Analyst .